The mammalian cell expressed PD-1 protein and toripalimab-Fab fragment were mixed at a molar ration of 1:1. The mixture was incubated on ice for 30 min and further purified by SuperdexTM 200 10/300 GL (GE Healthcare). 10 mg/mL of toripalimab/PD-1 proteins were used for crystal screening by vapour-diffusion sitting-drop method at 4°C. Diffractable crystals were obtained in a condition consisting of 0.09 M Halogens consisting of NaF, NaBr and NaI additives, 0.1 M Tris-Base (pH8.5), 37.5% (v/v) MPD-P1K-P3350 consisting of MPD (racemic), PEG 1K and PEG 3350 (Morpheus® MD1–46 kit, Molecular Dimensions).
Copyright: Content may be subjected to copyright.
How to cite:
Readers should cite both the Bio-protocol preprint and the original research article where this protocol was used:
Tan, S, Feng, H and Yan, J(2021). Complex preparation and crystallization. Bio-protocol Preprint. bio-protocol.org/prep1258.
Liu, H., Guo, L., Zhang, J., Zhou, Y., Zhou, J., Yao, J., Wu, H., Yao, S., Chen, B., Chai, Y., Qi, J., Gao, G. F., Tan, S., Feng, H. and Yan, J.(2019). Glycosylation-independent binding of monoclonal antibody toripalimab to FG loop of PD-1 for tumor immune checkpoint therapy. mAbs 11(4). DOI: 10.1080/19420862.2019.1596513
Post your question to gather feedback from the community. We will also invite the authors of this
article to respond.
0/150
Tips for asking effective questions
+ Description
Write a detailed description. Include all information that will help others answer your question including experimental processes, conditions, and relevant images.
Spinning
Post a Question
0 Q&A
Spinning
This protocol preprint was submitted via the "Request
a Protocol" track.